^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ABSK051

i
Other names: ABSK051
Associations
Trials
Company:
Abbisko
Drug class:
CD73 inhibitor
Associations
Trials
over1year
A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models (AACR 2023)
A set of immuno-oncology reagents, including anti-PD-1/L1, CSF-1R inhibitor (ABSK021) and CD73 inhibitor (ABSK051) were also tested in combination with ABSK071 in vivo using mouse syngeneic models. ABSK071 demonstrated much stronger inhibitory activity than sotorasib and adagrasib against a variety of cell lines harboring KRASG12C, as well as significantly better in vivo anti-tumor efficacy in xenograft models that were less sensitive to sotorasib. Synergistic effects on cell growth inhibition were observed in vitro with ABSK071 in combination with several agents including cetuximab, afatinib, AZD4547, TNO-155, RMC-4630 and BI3406... ABSK071 is a next-generation KRASG12C inhibitor with greater activity and anti-tumor efficacy in vitro and in vivo. It also demonstrated broad synergistic effects with a large set of targeted agents and immuno-oncology agents, indicating its strong potential in combinatory therapy in treating a wider range of KRASG12C-dependent cancers.
Preclinical • Late-breaking abstract • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
|
Erbitux (cetuximab) • Gilotrif (afatinib) • Lumakras (sotorasib) • Krazati (adagrasib) • fexagratinib (ABSK091) • BI-3406 • batoprotafib (TNO155) • vociprotafib (RMC-4630) • ABSK071 • pimicotinib (ABSK021) • ABSK051